Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

Phase I Clinical Trial of Tolerability and Pharmacokinetics of TQB3702 Tablets in Hematologic Tumor Subjects

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and preliminary efficacy of TQB3702 tablets in hematological tumor subjects.

Study Overview

• Status: Not yet recruiting
• Conditions: Hematologic Malignancy
• Intervention / Treatment: Drug: TQB3702 tablets

• Study Type: Interventional
• Enrollment (Anticipated): 137
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Zengjun Li, Doctor; Phone Number: +86-13642138692; Email: zengjunli@163.com
• Study Contact Backup: Name: Fei Li, Doctor; Phone Number: +86-13970038386; Email: yx021021@sina.com

Study Locations

• China
  • Jiangxi
    • Nanchang, Jiangxi, China, 330006
      • The First Affiliated Hospital Of Nanchang University
      • Contact: Fei Li, Doctor; Phone Number: +86-13970038386; Email: yx021021@sina.com
  • Shandong
    • Jinan, Shandong, China, 250117
      • The Cancer Hospital Affiliated to Shandong First Medical University
      • Contact: Zengjun Li, Doctor; Phone Number: +86-13642138692; Email: zengjunli@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects voluntarily joined the study, signed informed consent form, and with good compliance.
• ≥18 years old and ≤ 80 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-2; at least 3 months expected survival period.
• Clearly diagnosed recurrent / refractory hematological tumors that meet the WHO definition;
• At least 1 measurable lesion for efficacy evaluation.
• The function of main organs is normal.
• Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; a negative serum pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.

Exclusion Criteria:

• Patients has had or is currently having other malignant tumors within 3 years. The following two conditions can be included in the group: other malignant tumors treated with a single operation to achieved 5 consecutive years of disease free survival (DFS)s. Cured cervical carcinoma in situ, non-melanoma skin cancer, nasopharyngeal carcinoma and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)].
• Subjects with central nervous system aggression (CNS);
• Received allogeneic hematopoietic stem cell transplantation (allo-HSCT) or had active graft-versus-host disease (GVHD) requiring immunosuppressive therapy within 12 months before the first dose;
• Multiple factors that affect the absorption of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction);
• Unrelieved toxicity of ≥CTC AE grade 1 due to any previous treatment, excluding alopecia and fatigue;
• Major surgical treatment, open biopsy, and significant traumatic injury were received within 28 days before the start of study treatment.
• The presence of active or uncontrolled primary autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) and primary immune thrombocytopenia (ITP);
• Patients with evidence or history of bleeding constitution; Or any bleeding event (such as gastrointestinal bleeding) greater than or equal to CTC AE level 3 within 4 weeks before the first medication;
• Subjects had an arteriovenous thrombosis event within 6 months.
• Subjects have history of psychotropic substance abuse and are unable to abstain or have mental disorders;
• Subjects with any severe and/or uncontrolled disease.
• Within 2 weeks before the first treatment, the subjects had received proprietary Chinese medicines with anti-tumor indications specified in the NMPA approved drug instructions;
• Uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage (investigator judgment);
• Study treatment related: subjects received live or mRNA vaccines within 4 weeks before the first treatment or were scheduled to receive live or mRNA vaccines during the study;
• Participated in clinical trials of other antitumor drugs within 4 weeks before the first treatment;
• According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TQB3702 tablets; TQB3702 tablets were administered orally, 28 days as a treatment cycle until the progressive diseases or the investigator judges that it is not suitable for subject to continue to take this medicine.	Drug: TQB3702 tablets; TQB3702 tablets are selective BTK inhibitors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	To evaluate the maximum tolerated dose of TQB3702 tablets in the treatment of relapsed/refractory hematologic tumors.	Baseline up to 104 weeks
Dose limited toxicity (DLT)	To evaluate the dose-limiting toxic dose of TQB3702 tablets in the treatment of relapsed/refractory hematologic tumors.	Baseline up to 104 weeks
Recommended Phase II Dose (RP2D)	To evaluate the phase II recommended dose of TQB3702 tablets in the treatment of relapsed/refractory hematological tumors.	Baseline up to 104 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Reach the Maximum Plasma Concentration (Tmax)-single dose	Time to Reach the Maximum Plasma Concentration after single dose	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Time to Reach the Maximum Plasma Concentration (Tmax)-multiple dose	Time to Reach the Maximum Plasma Concentration after multiple dose	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Maximum plasma concentration (Cmax)-Single dose	Cmax is the maximum plasma concentration of TQB3702 after single dose	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Maximum plasma concentration (Cmax)-Multiple dose	Cmax is the maximum plasma concentration of TQB3702 after multiple dose	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Elimination half-life (t1/2)-Single dose	t1/2 is time it takes for the blood concentration of TQB3702 or metabolite(s) to drop by half after single dose.	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72 hours after administration.
Elimination half-life (t1/2)-Multiple dose	t1/2 is time it takes for the blood concentration of TQB3702 or metabolite(s) to drop by half after multiple dose.	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)-Single dose	To characterize the pharmacokinetics of TQB3702 by assessment of area under the plasma concentration time curve from the first dose to a certain time.	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Area under the plasma concentration-time curve from time zero to time t (AUC0-t)-Multiple dose	To characterize the pharmacokinetics of TQB3702 by assessment of area under the plasma concentration time curve from the first dose to a certain time.	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)-Single dose	Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss) after Single dose	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)-Multiple dose	Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss) after Multiple dose	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss)-single dose	steady state area under the concentration-time curve over a dosing interval (AUCtau, ss) after single dose	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
steady state area under the concentration-time curve over a dosing interval (AUCtau, ss)-multiple dose	steady state area under the concentration-time curve over a dosing interval (AUCtau, ss) after multiple dose	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Minimum steady-state plasma drug concentration during a dosage interval (Css-min)-Single dose	Minimum steady-state plasma drug concentration during a dosage interval (Cmin-ss) after Single dose	before administration, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24, 48, 72hours after administration.
Minimum steady-state plasma drug concentration during a dosage interval (Css-min)-multiple dose	Minimum steady-state plasma drug concentration during a dosage interval (Cmin-ss) after multiple dose	before administration (-1~0h), 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 24 hours after administration at Day 8/15/28 of Cycle1, Day 28 of Cycle 6; when withdrawn from the group due to disease progression or at the end of study treatment.
Objective Response Rate (ORR)	The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period	Baseline up to 104 weeks
Complete Remission Rate (CRR)	The proportion of tumors that have a complete response after treatment	Baseline up to 104 weeks
Disease Control Rate (DCR)	The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a cancer treatment in clinical trials.	Baseline up to 104 weeks
Duration of Response (DOR)	The time from the date of first documentation of a CR or PR or PD to the date of first documentation of tumor progression.	Baseline up to 104 weeks
Progression Free Survival (PFS)	The time from the first dose to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first	Baseline up to 104 weeks
Overall Survival (OS)	the time from start of study treatment to date of death due to any cause	Baseline up to 104 weeks
Adverse events (AE)	The occurrence of all adverse events (AE)	Baseline up to 104 weeks
Serious adverse events (SAE)	The occurrence of all serious adverse events (SAE)	Baseline up to 104 weeks
Bruton's tyrosine kinase (BTK) occupancy	The BTK occupancy in peripheral blood mononuclear cell (PMBC)	Baseline up to 104 weeks

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2022
• Primary Completion (Anticipated): August 1, 2024
• Study Completion (Anticipated): August 1, 2024

Study Registration Dates

• First Submitted: November 2, 2022
• First Submitted That Met QC Criteria: November 2, 2022
• First Posted (Actual): November 9, 2022

Study Record Updates

• Last Update Posted (Actual): November 9, 2022
• Last Update Submitted That Met QC Criteria: November 2, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Site; Hematologic Diseases; Hematologic Neoplasms
• Other Study ID Numbers: TQB3702-I-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No